Synapse by Bioscript Data and Insights: The evolution of data-driven decision-making

In today’s pharmaceutical landscape, leveraging data is crucial for strategic gain. For some time now, Bioscript Group has been quietly revolutionising how our clients interact with complex information, empowering them with smarter planning, sharper strategies and deeper scientific insights. Bioscript Data-Led Insights (BDI) capability has been transforming data into actionable intelligence, with remarkable results.

Now, we are ready to announce the next evolution of this capability: Synapse by BDI. Synapse represents the culmination of our commitment to delivering cutting-edge data intelligence.

You might already be familiar with some of the powerful tools and insights that form the backbone of Synapse, as our clients have been leveraging them to great effect. Synapse is using existing and new tools to drive tangible value for businesses globally:

• Key opinion leader (KOL) mapping dashboard
  
  A vital tool for identifying, engaging and influencing the most impactful voices in any therapeutic area. By integrating multi-source data — from publications to social media — and offering intuitive visualisations, this dashboard allows teams to pinpoint emerging and established KOLs, understand their influence networks and prioritise engagement strategies. Whether launching a new product or expanding into new markets, our dashboard ensures you are connected to the right experts at the right time.
• Congress intelligence dashboard
  
  This dashboard provides real-time insights from major scientific congresses, offering live updates on sessions, speakers and social media buzz. It enables KOL and digital opinion leader (DOL) tracking to monitor influence and reach, with enhanced UI features such as collapsible filters, abstract tagging and media integration, providing a seamless user experience. Medical affairs, commercial teams and strategic planners are already leveraging this cutting-edge technology to gain access to rapid insights from medical congresses.
• Evidence generation dashboard
  
  This capability has been instrumental in transforming complex scientific output into compelling narratives. Our clients are using it to visualise publication trends, authorship networks and citation impact, enabling them to identify evidence gaps and opportunities for new research. This tool is designed for teams who need to communicate scientific value with precision and impact, supporting strategic planning and client storytelling with data-driven clarity.
• Predictive publication planning
  
  This capability provides a critical edge in today’s competitive landscape where timing is everything. Our clients are already using it to forecast where, when and what publications are likely to appear across clinical development phases. This enables them to choose between staggered or same-day publication strategies to maximise academic influence and public engagement, with predicted outputs visualised on dashboards to inform communication planning and resource allocation.

While these powerful tools and insights have already been delivering significant benefits, Synapse will provide these capabilities in a more packaged and user-friendly format in September. This will be a fully integrated, intuitive platform, meticulously designed to support both global strategy and on-the-ground execution.

Augmented with AI, Synapse is a solution for transforming complex data into powerful, actionable insights. It adapts to clients’ unique needs, delivering tailored insights that drive success. Congress intelligence, KOL and evidence generation insights are all brought together for truly data-driven strategic decision-making. Synapse will allow our clients to maximise the potential of their products with its powerful data capabilities.